We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+23.95%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.74B
AUM Growth
+$946M
Cap. Flow
+$105M
Cap. Flow %
1.56%
Top 10 Hldgs %
63.65%
Holding
393
New
188
Increased
79
Reduced
42
Closed
65

Top Buys

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$76M
2
NVO
Novo Nordisk
NVO
+$43.1M
3
FRPT icon
Freshpet
FRPT
+$41.5M
4
SBUX icon
Starbucks
SBUX
+$31.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$30.3M

Top Sells

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$79.6M
2
PTCT icon
PTC Therapeutics
PTCT
+$76M
3
GRFS
Grifois
GRFS
+$50.6M
4
STAA icon
STAAR Surgical
STAA
+$47.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$40.5M

Sector Composition

Rank Sector Weight
1 Healthcare 31.9%
2 Technology 5.53%
3 Consumer Discretionary 5.27%
4 Communication Services 2.01%
5 Consumer Staples 1.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IWM icon
1
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$1.69B 25.12%
7,000,000
– –
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$1.67B 24.71%
2,500,000
+50,000
+2% +$32.1M
PTCT icon
3
PTC Therapeutics
PTCT
$6.37B
$201M 2.98%
3,277,272
-1,458,192
-31% -$76M
TVTX icon
4
Travere Therapeutics
TVTX
$5.33B
$161M 2.38%
6,724,000
-2,152,000
-24% -$40.5M
SUPN icon
5
Supernus Pharmaceuticals
SUPN
$2.68B
$136M 2.01%
2,836,000
-1,976,000
-41% -$79.6M
INCY icon
6
Incyte
INCY
$23.5B
$99M 1.47%
1,167,431
-168,569
-13% -$13.3M
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.7B
$97.8M 1.45%
697,022
+20,998
+3% +$2.85M
IMVT icon
8
Immunovant
IMVT
$8.09B
$94.1M 1.4%
5,836,000
+636,000
+12% +$10.3M
XRAY icon
9
Dentsply Sirona
XRAY
$2.59B
$72.8M 1.08%
5,736,000
+5,234,587
+1,044% +$76M
REGN icon
10
Regeneron Pharmaceuticals
REGN
$68.8B
$70.4M 1.04%
125,206
+25,174
+25% +$14.2M
FRPT icon
11
Freshpet
FRPT
$2.83B
$68M 1.01%
1,234,802
+669,399
+118% +$41.5M
AMZN icon
12
Amazon
AMZN
$2.5T
$67.9M 1.01%
309,400
+89,977
+41% +$20.4M
CYTK icon
13
Cytokinetics
CYTK
$11B
$65.8M 0.98%
1,196,868
-115,481
-9% -$4.76M
GEHC icon
14
GE HealthCare
GEHC
$27.6B
$59.7M 0.89%
795,053
+38,772
+5% +$2.89M
MDGL icon
15
CALL
Madrigal Pharmaceuticals
MDGL
$12.6B
$59.6M 0.88%
130,000
-40,000
-24% -$14.9M
EXAS
16
DELISTED
Exact Sciences
EXAS
$56.4M 0.84%
1,030,465
+288,509
+39% +$14.4M
GOOGL icon
17
Alphabet (Google) Class A
GOOGL
$3.91T
$56.1M 0.83%
230,681
+40,281
+21% +$8.44M
MDGL icon
18
Madrigal Pharmaceuticals
MDGL
$12.6B
$55M 0.82%
119,982
-4,018
-3% -$1.5M
CYTK icon
19
CALL
Cytokinetics
CYTK
$11B
$52.2M 0.77%
950,000
-390,000
-29% -$16.1M
FIVN icon
20
FIVE9
FIVN
$1.77B
$48.4M 0.72%
2,000,000
+164,000
+9% +$4.34M
MSFT icon
21
Microsoft
MSFT
$2.84T
$45.2M 0.67%
87,245
+3,508
+4% +$1.79M
ARGX icon
22
argenx
ARGX
$57.4B
$42.8M 0.63%
58,000
-22,000
-28% -$14.5M
TMCI icon
23
Treace Medical Concepts
TMCI
$259M
$42.4M 0.63%
6,316,000
+56,000
+0.9% +$366K
KURA icon
24
Kura Oncology
KURA
$922M
$41.3M 0.61%
4,672,000
-1,528,000
-25% -$10.9M
NVO
25
Novo Nordisk
NVO
$216B
$40.8M 0.61%
+736,000
New +$43.1M
1
2 3 4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.61B AUM 19.63% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
AIM
Alphinity Investment Management Sydney, Australia $5.68B AUM 26.72% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return

Armistice Capital's Q3 2025 Portfolio in Review

As of Q3 2025, Armistice Capital held 393 positions worth $6.74B, up 16% from $5.8B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Armistice Capital's Q3 2025 filing shows 188 new, 79 increased, 42 reduced and 65 closed positions. Its largest new stake was Novo Nordisk: 736,000 shares worth $40.8M. The largest sale was Supernus Pharmaceuticals, an estimated $79.6M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Armistice Capital's largest Q3 2025 buy was Novo Nordisk: 736,000 shares worth $40.8M.
  • Armistice Capital added most to Dentsply Sirona in Q3 2025, an estimated $76M increase.
  • Armistice Capital's biggest Q3 2025 reduction was Supernus Pharmaceuticals, cutting an estimated $79.6M.
  • Armistice Capital fully exited STAAR Surgical in Q3 2025, selling an estimated $47.2M.
  • Armistice Capital's ten largest holdings make up 64% of its $6.74B portfolio in Q3 2025.
  • Armistice Capital opened 188 new positions and closed 65 in Q3 2025.
  • Armistice Capital's portfolio value rose 16% quarter-over-quarter to $6.74B.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.